Combinations of eszopiclone and O-desmethylvenlafaxine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders

A technology for eszopiclone and mood disorders, applied in the composition of anxiety disorders and cognitive disorders, in the field of treatment of menopause and mood disorders, and can solve problems such as inability to improve cognitive function

Inactive Publication Date: 2008-09-03
SEPACOR INC
View PDF11 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, some experts believe that removing hematomas does little to improve cognitive function after they have put pressure on the brain for a long time (perhaps a year or more)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combinations of eszopiclone and O-desmethylvenlafaxine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
  • Combinations of eszopiclone and O-desmethylvenlafaxine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
  • Combinations of eszopiclone and O-desmethylvenlafaxine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0114] Example 1. Dosage Form

[0115] The following dosage form is an example of a combination tablet or capsule of eszopiclone and O-desmethylvenlafaxine:

[0116] Table 1. Combination dosage forms of eszopiclone and (-)-O-DMV

[0117]

[0118] Table 2. Combination Dosage Forms of Eszopiclone and Racemic O-DMV

[0119]

[0120]

[0121] * 1.0 mg O-DMV free base is equivalent to 1.517 mg succinate monohydrate salt.

[0122] Above-mentioned dosage form can carry out following steps to prepare:

[0123] 1. Screening eszopiclone by 80 mesh.

[0124] 2. Screen O-DMV through 40 mesh.

[0125] 3. Sift remaining ingredients through #20 or #30 mesh sieve.

[0126] 4. Mix eszopiclone and part of MCC (microcrystalline cellulose).

[0127] 5. Mix O-DMV with the mixture from step 4.

[0128] 6. Mix the mixture from step 5 with the remaining MCC from step 3.

[0129] 7. Mix the mixture from step 6 with the dicalcium phosphate.

[0130] 8. Mix the croscarmellose with the s...

Embodiment 2

[0135] Example 2. Clinical research on the treatment of menopause or perimenopause with eszopiclone

[0136] The aim of the study was to observe the efficacy of eszopiclone 3 mg compared with placebo in the treatment of insomnia secondary to perimenopause or menopause.

[0137] The study was a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. The study had a one-week single-blind placebo enrollment period, followed by four weeks of double-blind treatment and a one-week single-blind placebo wash-out. The preliminary method of analysis compared post-randomization results between the two treatment groups.

[0138] The subjects were women with insomnia secondary to perimenopause or menopause. Subjects are pre-menopausal or menopausal and suffer from insomnia symptoms, including sleep latency (SL) ≥ 45 minutes and total sleep time (TST) ≤ 6 hours. Perimenopausal / menopausal symptoms precede sleep disturbance symptoms. The patient population was pre...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is O-desmethylvenlafaxine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.

Description

field of invention [0001] The present invention relates to compositions and methods for treating menopause and mood disorders, anxiety disorders and cognitive disorders. Background of the invention [0002] Menopause, caused by decreased production of female sex hormones, typically occurs around age 50 but can occur at much earlier or later ages and can produce disturbances such as edema, hot flashes (or flushes), Sweating, muscle pain and possibly joint pain, sleep disturbance, restlessness, nervousness, mood swings, headache, palpitations (increased heart rate frequency), dry mucous membranes, pain during intercourse, and urinary disturbance. Hot flashes, or flushes, are characterized by sudden warmth in the face and neck, often spreading to the chest. Attacks usually last a few minutes and are manifested by visible flushing of the skin. Often such episodes are accompanied by diaphoresis, dizziness, nausea, palpitations, and sweating. Such symptoms can disrupt sleep and...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/135A61K31/495
CPCA61K31/137A61K31/4985A61P15/08A61P25/14A61P25/16A61P25/18A61P25/20A61P25/22A61P25/24A61P25/28A61P43/00A61K2300/00
Inventor J·卡伦T·韦塞尔K·拉尔吉M·A·瓦尼
Owner SEPACOR INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap